Assignee
PROLYNX LLC
US13 patents
Top patents by PatentIndex Score
US9387254B2Jul 12, 2016
Prodrugs and drug-macromolecule conjugates having controlled drug release rates
PROLYNX LLC9 citations84
US11179470B2Nov 23, 2021
Hydrogels with biodegradable crosslinking
PROLYNX LLC7 citations82
US10398779B2Sep 3, 2019
Hydrogels with biodegradable crosslinking
PROLYNX LLC4 citations82
US11454861B2Sep 27, 2022
Hydrogels with biodegradable crosslinking
PROLYNX LLC2 citations71
US11181803B2Nov 23, 2021
Hydrogels with biodegradable crosslinking
PROLYNX LLC2 citations71
US10016411B2Jul 10, 2018
Slow-release conjugates of SN-38
PROLYNX LLC2 citations70
US12478680B2Nov 25, 2025
Hydrogels with biodegradable crosslinking
PROLYNX LLC0 citations61
US10342792B2Jul 9, 2019
Slow-release conjugates of SN-38
PROLYNX LLC1 citations59
US11730836B2Aug 22, 2023
Synergistic cancer treatment
PROLYNX LLC0 citations54
US10413594B2Sep 17, 2019
Conjugates of somatostatin analogues
PROLYNX LLC0 citations49
US10086049B2Oct 2, 2018
Conjugates of somatostatin analogues
PROLYNX LLC0 citations49
US12472261B2Nov 18, 2025
Conjugated inhibitors of DNA damage response
PROLYNX LLC0 citations48
US12364771B2Jul 22, 2025
Conjugation linkers
PROLYNX LLC0 citations45